CLINICAL FIBROSIS OF THE
Neuromuscular diseases (NMDs) such as Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA) lead to the loss of muscle function and eventually to death. Current diagnostic methods rely on subjective physiological examinations such as the six-minute walk test (6-MWT). With promising yet extremely expensive therapeutics coming to market, an objective method of assessing disease status is critical. MSOT has shown the potential to be such a method, by quantifying the collagen concentration in muscle tissue as a biomarker of tissue degeneration.